Zomedica Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZOM research report →
Price Chart
About the company
Zomedica Corp. is a veterinary healthcare enterprise dedicated to fulfilling the specific needs of clinical veterinarians through the creation of products for companion animals. The company is actively involved in the development and market introduction of its TRUFORMA platform, which delivers point-of-care diagnostic tools for various canine and feline illnesses.
- CEO
- Larry C. Heaton II
- IPO
- 2017
- Employees
- 144
- HQ
- Ann Arbor, MI, US
Get TickerSpark's AI analysis on ZOM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $95.35M
- P/E
- -6.32
- PEG
- 0.06
- P/S
- 2.53
- P/B
- 0.91
- EV/EBITDA
- -9.15
- Div Yield
- 0.00%
- Gross Margin
- 62.59%
- Op Margin
- -43.72%
- Net Margin
- -40.37%
- ROE
- -14.17%
- ROIC
- -15.46%
Latest fiscal year · YoY change
- Revenue
- $32.03M+17.4%
- Gross Profit
- $21.68M+13.6%
- Op Income
- $-84,353,000
- Net Income
- $-81,858,000-74.2%
- EPS
- $-0.08-66.7%
- OCF Growth
- +25.3%
- FCF Growth
- +42.0%
- 52W High
- $0.20
- 52W Low
- $0.02
- 50D MA
- $0.11
- 200D MA
- $0.13
- Beta
- 1.16
- RSI (14)
- 41
- Avg Volume
- 8.54M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Zomedica posted record Q3 revenue growth, strong gross margin and improving cash burn, while management said 2025 should accelerate on new products, international expansion and a rebuilt sales force.· November 7, 2024
- Revenue hit a new Q3 record of $7 million, up 10.2% year over year, marking the 14th straight quarter of record quarterly revenue.
- Gross margin was 72.3%, above the company’s prior 65% to 70% target range and higher than 69% a year ago.
- Operating expenses were $12.5 million, up 21% year over year but down $900,000 sequentially as one-time costs eased.
- Cash used in the quarter fell to $5.1 million, with adjusted operating cash burn of $4 million, showing better efficiency through 2024.
- Management expects fourth-quarter strength from seasonally better Assisi sales and new assay launches, and said 2025 should bring accelerated growth and more international contribution.
Zomedica reported third-quarter 2024 revenue of $7 million, up 10.2% year over year. Capital revenue was $2.2 million, up over 21%; consumable revenue was $4.8 million, up approximately 6%, or 27% excluding Assisi products. Therapeutic Devices revenue was $6.5 million, up 8.5%, with PulseVet up 24.5% or $1.1 million; Diagnostics revenue was about $500,000, up 38%, driven mainly by TRUFORMA growth. Gross margin was 72.3%, versus 69% last year. Net loss was $6.7 million, or $0.007 per share, versus a net loss of $491,000, or $0.0005 per share, in the prior-year quarter. Non-GAAP EBITDA loss was $4.8 million, and adjusted non-GAAP EBITDA loss was about $4.3 million. Operating expenses were $12.5 million, up 21% year over year, but down $900,000 or 7% sequentially. Zomedica ended the quarter with $77.8 million in cash, cash equivalents and available-for-sale securities; cash used was $5.1 million and adjusted operating cash burn was $4 million. Management did not provide formal numeric guidance for the next quarter or full year, but said the fourth quarter should benefit from seasonal strength in Assisi and continued capital-sales recovery, while international revenue should be a material growth driver in 2025 and beyond. Larry Heaton reiterated that the company expects to be cash flow positive once it reaches $50 million in annualized revenue and said that prior timing of late 2025 had been too aggressive, with 2026 now framed as the more realistic target.
Larry Heaton struck an upbeat tone, saying the quarter was strong and that the company is seeing momentum across its five product lines, especially PulseVet, TRUFORMA, and VetGuardian. He emphasized that the rebuilt sales force, new international distributor relationships, and new product launches should help growth accelerate in 2025. He also highlighted that Zomedica now has CE Marking across products and that international expansion is becoming a larger part of the strategy.
Mike Zuehlke focused on the improving financial profile: 72.3% gross margin, $12.5 million of operating expenses, and a $5.1 million cash use figure that included $1.1 million of non-recurring items. He also pointed to declining cash burn year to date, with total quarterly cash use moving from $9.6 million to $7.9 million to $5.1 million and adjusted operating cash burn falling from $6.9 million to $5.2 million to $4 million. He noted zero debt and nearly $78 million in liquidity, and said the company believes it is well funded for organic growth and potential acquisitions.
Analysts asked about the rebound in capital sales after second-quarter salesforce disruptions, and management said five reps had been out on medical leave but the team returned to full strength in Q3, driving a 24% increase in PulseVet capital sales and a recovery in new installations. Questions also focused on profitability timing, delisting risk, and capital allocation; Heaton said cash flow positive is expected at $50 million in annualized revenue, that 2026 is now the more realistic timing versus the earlier late-2025 goal, and that the company does not plan a buyback. He also said delisting is a risk below the exchange threshold but noted ongoing dialogue with the exchange and strong liquidity.
The company is showing record revenue growth, high gross margins, and improving cash burn, while management says the quarter’s operational issues are behind them. New assay launches, CE Marking, distributor expansion, and a larger sales force could support further growth, and management believes international revenue can become a material contributor in 2025 and beyond.
Profitability is still distant, with a $6.7 million quarterly net loss and management pushing out the expected cash flow breakeven timeline from late 2025 toward 2026. The stock remains exposed to delisting risk because it is below the exchange threshold, and management acknowledged that some 2024 growth was disrupted by salesforce absences, macro interest-rate concerns, and a softer animal health market.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.1%
- Shares Outstanding
- 979.95M
- Float Shares
- 961.65M
of shares held by institutions
95 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 9.86M | 0 |
| Orion Portfolio Solutions, LLC | 357.15K | 0 |
| Tallon Kerry Patrick | 150.00K | ▲ 150.00K |
| Planning Capital Management Corp | 1.60K | ▲ 1.60K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 17, 25 | Rowe Jeffrey M | buy | 731,368 |
| Mar 17, 25 | Rowe Jeffrey M | buy | 34,725 |
| Mar 17, 25 | Rowe Jeffrey M | buy | 4,265 |
| Mar 17, 25 | Rowe Jeffrey M | buy | 68,000 |
| Mar 17, 25 | Rowe Jeffrey M | buy | 100,647 |
| Mar 17, 25 | Rowe Jeffrey M | buy | 500,000 |
| Mar 17, 25 | Williams Rodney James | buy | 100,000 |
| Mar 17, 25 | Jordan Scott | buy | 300,000 |
| Mar 17, 25 | Rowe Jeffrey M | buy | 34,725 |
| Mar 17, 25 | Rowe Jeffrey M | buy | 4,265 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZOM coverage
Recent articles, reports, and earnings notes.
No research on ZOM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZOM report →Zomedica Corp. (ZOMDF) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 20
Zomedica Corp. (ZOMDF) Discusses Clinical Program and Evidence-Driven Adoption in Veterinary Products Transcript
seekingalpha.com · Oct 24
Zomedica Announces "Fourth Friday at Four" Webinar on October 23, 2026: Zomedica's Clinical Program: How Evidence Drives Adoption
accessnewswire.com · Oct 8
Zomedica Corp. (ZOMDF) Inside Marketing: How Demand Creation Drives Revenue and Supports Distinct Product Portfolios Transcript
seekingalpha.com · Sep 26
Zomedica Announces Strategic Partnership with Veterinary Study Groups (VMG) to Deliver Advanced Veterinary Technologies to Independent Practices
accessnewswire.com · Sep 22
Zomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica's Marketing Engine: How Demand Becomes Revenue
accessnewswire.com · Sep 9
Zomedica Corp. (ZOMDF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 28
Zomedica Announces "Fourth Friday at Four" Webinar on August 28, 2026: Zomedica International: Building a Global Platform for Veterinary Innovation
accessnewswire.com · Aug 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.